Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Goldman Sachs Group Inc (GS) Price & Performance

Abeona Therapeutics IncTrade
Goldman Sachs Group IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Goldman Sachs Group Inc — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while Goldman Sachs Group Inc trades at $1,033.55 (market cap $301.19B). The key difference: Goldman Sachs Group Inc is far larger — about 715.1× Abeona Therapeutics Inc's market cap, and Goldman Sachs Group Inc pays a 1.93% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOGS
Market Cap
$421.19M$301.19B
Sector
HealthFinancials
52-Week High
$7.45$1.15K
52-Week Low
$4.17$715.95
Enterprise Value
$276.10M
Volume
2,592,735
Dividend Yield
1.93%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.

Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.

Goldman Sachs Group Inc

Goldman Sachs (GS) trades at $1,034.51, down 0.49% on the day, with a neutral technical signal and strong fundamental performance. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $20.98 surpassing the $14.47 estimate. Revenue growth is robust, rising to $58.28 billion in 2025, and net income margin expanded to 31.68%. The company is positioned to benefit from a surge in investment banking activity, including leading high-profile IPOs like Anthropic.

The outlook is positive given earnings momentum and strategic positioning in key deals, but risks include volatile cash flows and high leverage. Analyst consensus is a Buy with a $1,160 price target, implying potential upside. Investors should weigh strong profitability against macroeconomic sensitivity and balance sheet pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Goldman Sachs Group Inc

The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.

Read more on GS